BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 4
• 5
• 6
• 7
• 8
• 11
• 12
• 13
• 14
• 15
• 18
• 19
• 20
• 21
• 22
• 25
• 26
• 27
• 28
• 29
• 30

• Drug Development

  Lee Moffitt Cancer Center & Research Institute Release: Revlimid Data Presented at American Society of Clinical Oncology Demonstrates Impressive Survival Benefit and Stands to Change the Way Physicians Treat Multiple Myeloma

  June 4, 2007

   · 

  3 min read
• Drug Development

  Survival Benefit Demonstrated in Placebo-Controlled Trial in Patients with Refractory Non-Small Cell Lung Cancer Treated with Agennix’s Oral Talactoferrin

  June 4, 2007

   · 

  4 min read
• Pharm Country

  Milestone Scientific’s STA(TM) System Named By Dentistry Today as One of ‘2007 Top 100 Products’

  June 4, 2007

   · 

  3 min read
• Drug Development

  Exelixis, Inc. Reports Comprehensive XL880 Phase I Data At American Society of Clinical Oncology

  June 4, 2007

   · 

  5 min read
• Drug Development

  CuraGen Corporation Announces Presentations and Published Abstracts on Belinostat at American Society of Clinical Oncology 2007 Annual Meeting and 2007 Pan Pacific Lymphoma Conference

  June 4, 2007

   · 

  6 min read
• Drug Development

  Oxford BioMedica PLC and Sanofi-Aventis (France) Report new TroVax(R) Phase II Trial Results in Renal Cancer

  June 4, 2007

   · 

  9 min read
• Drug Development

  Bristol-Myers Squibb Company Phase III Ixabepilone Study Demonstrated Significant Improvement in Progression-Free Survival in Patients With Advanced Metastatic Breast Cancer

  June 4, 2007

   · 

  4 min read
• Drug Development

  Millennium Pharmaceuticals, Inc. (Cambridge, Massachusetts) VELCADE(R) (bortezomib) for Injection Based Therapies Produced High Complete Response Rates in Newly Diagnosed Non-Hodgkin’s Lymphoma Patients

  June 4, 2007

   · 

  9 min read
• Drug Development

  Favrille, Inc. Reports Status of Phase 2 Clinical Trial of FavId With Maintenance Rituxan for Indolent B-Cell Non-Hodgkin’s Lymphoma

  June 4, 2007

   · 

  4 min read
• Business

  Haemacure Corporation Reports Second Quarter 2007 Results

  June 4, 2007

   · 

  3 min read